After years of debate, the Food and Drug Administration has withdrawn a rule that would have allowed generic drug makers to unilaterally update their product labeling when they learn of new information.

In explaining its reasons, the agency worried the rule could create “unintended consequences” by confusing patients and doctors if some generic companies did not revise labeling on a timely basis, or if generic and brand labels appeared different. FDA officials also pointed to concerns expressed by generic makers that they would have to raise prices to cover added costs for complying with the rule.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • let’s be clear – this isn’t about ALLOWING generics manufacturers to update the labels of the drugs they sell, they’re complaining because the regulation would COMPEL them to.
    Making the original company responsible when the brand has lost patent protection and so they’ve lost essentially all profit on that product seems unfair at best and frankly irrational. Once generics companies are making all the $ on a drug (and let’s be clear, on many of these generics they’re making tens of millions per year), they should bear responsibility, in concert with the FDA, to adjust labels as new data (usually safety) becomes known. The generic company’s complaint is essentially that this is a cost that cuts into their profits. Patient safety and prescriber confusion arguments are obfuscation, pure and simple.

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy